IGI Logo
Toggle Navigation
News
Hindi
Hindi News
Top News
Screeners
Stocks
Stocks Screener
Stock
News
Stock Market Home Page
Stock News
Industry News
Economy News
Stock on the move
Expert Views
Research Reports
Company Result
Comp Info And Fundamentals
Company Profile
Equity
Financial Ratios
Results
Balance Sheet
Profit And Loss
Cash Flow
Share Holding
Derivatives (F&O)
Get Quotes
Market Watch
Top Gainers
Top Losers
Top Traded Quantity
Top Traded Value
Most Active Puts
Derivatives (F&O)
Most Active Calls
Put Call Ratio
Highest In Premium
Daily Settlement Price
FII and DII Statistics
Open Interest: Highest In OI
Open Interest: Lowest In OI
Derivatives (F&O)
Open Interest: Increase in OI Increase in Price
Open Interest: Decline in OI Decrease in Price
Derivative Watch
Derivatives Dashboard
Historical Data
List of Underlyings & Underlying Info
Derivative Watch
Derivatives Dashboard
Market Reports
Top Gainers
Top Losers
Monthly High/Low
52 Week High
52 Week Low
Market Cap Gainers
Market Cap Losers
PE Ratio
>More Market Reports
IPO
News
IPO News
IPO Issue Reports
Commodity
Commodity Market
Commodity Home Page
Commodity News
Commodity Reports
Market Details
Get Quotes
Top Gainers
Top Losers
Top Volume
Top Value
Top Gainers Spot Market
Top Losers Spot Market
High & Low
Commodity Indices
Technical Analysis
Advance Declines
High & Low
Highest In OI
Lowest OI
Increase In Open Interest(%)
Descrease In Open Interest(%)
Currency
News
Currency News
Economy News
Currency Reports
Mutual Fund
News
Mutual Fund Home Page
Mutual Fund News
Mutual Fund Details
Mutual Fund Home Page
Compare Scheme
Scheme Profile
Mutual fund Investment
Mutual Fund Share Holding
Mutual Fund Statistics
Mutual fund Gainers
Mutual fund Losers
Biggest Schemes
Best Performers
Latest Dividend Details
Tools
Multi Scheme Comparison Tool
Dividend Details
Performance Map
Mutual fund Investment
Mutual fund Share Holding
Mutual Fund Search Category Rankings
Widgets
Stock Widgets
Watchlist
Heatmap
Mutual Fund Widgets
Watchlist
Calculators
EMI Calculator
SIP Calculator
SWP Calculator
GST Calculator
FD Calculator
RD Calculator
Wealth
World
Tips
Intraday Tips
Market Outlook
Stock Tips
Commodity Tips
Currency Tips
Reports
Short Term Investment Opportunities
Long Term Investment Opportunities
Sector Analysis
Commodity Reports
Currency Reports
Mutual Fund Analysis
Podcast
Videos
Videos Category
Business Videos
Budget Videos
News And Politics
Entertainment Videos
Sports Videos
Lifestyle And Fashion Videos
Global News Videos
Calculators
EMI Calculator
SIP Calculator
SWP Calculator
GST Calculator
FD Calculator
RD Calculator
More
Budget 2024
Astrology
Women
Politics
Entertainment
Car&Bike
Gadgets
Lifestyle
Sports
Health
Fashion
Diwali Reports
Diwali Expert Reports
News
Astrology
Beyond Market Car
Beyond Market Entertainment
Beyond Market Fashion
Beyond Market Gadgets
Beyond Market Health
Beyond Market India
Beyond Market Life Style
Beyond Market Sports
Broking Firm Views
Broking Firm Views - Long Term Report
Broking Firm Views - Sector Report
Broking Firm Views - Short Term Report
Budget 2024 Sector Reports
Budget Bites
Budget Economic Servey
Budget Expert Views
Budget Industry
Budget News
Budget Wishlist
Commodities
Commodities Reports
Commodity Top News
Company News
Company Result
Currency News
Currency Report
Currency Top News
Diwali Expert Views
Diwali Market Outlook
Diwali Report
Diwali Technical Report
Economy News
Expert View Institution
Expert Views
Industry News
IPO Analysis
IPO More News
IPO Reports
IPO Top News
Market Outlook
Mutual Fund Analysis
Mutual Fund Expert Views
Mutual Fund More News
Mutual Fund Top News
Podcast - Market Ki Awaaz
Special Event Expert Views
Special Event Reports
Startup
Startup Expections
Startup Speak
Stock Market
Stock On The Move
Top News
Top Stories
Videos
Videos Business
Videos Entertainment
Videos Global News
Videos Lifestyle And Fashion
Videos News And Politics
Videos Sports
Wealth
Women
World Market More News
World Top News
Search
Aurobindo Pharma is currently trading at Rs. 864.95, up by 2.00 points or 0.23% from its previous closing of Rs. 862.95 on the BSE. The scrip opened at Rs. 864.30 and has touched a high and low of Rs. 868.30 and Rs. 858.75 respectively. So far 27476 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 887.20 on 14-Aug-2023 and a 52 week low of Rs. 397.30 on 03-Feb-2023. Last one week high and low of the scrip stood a...
Aurobindo Pharma rises on getting EIR for Telangana manufacturing facility
Tata Consultancy Services Ltd Buy Tata Consultancy Services Ltd @3419-3423; Target 3457.00; Stop Loss 3403.00 Aurobindo Pharma Ltd Buy Aurobindo Pharma Ltd @ 848-850; Target 859.80; Stop Loss 843.80 To Read Complete Report & Disclaimer Click Here Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Disclaimer.html SEBI Registration number INZ000183631 Above views are of the author and...
Stock Picks : Tata Consultancy Services Ltd And Aurobindo Pharma Ltd By ICICI Direct
US/EU markets drive profitability Re-exploring restructuring of Eugia business * Aurobindo Pharma (ARBP) delivered operationally better-than-expected 1QFY24 performance, on the back of a healthy volume off-take in the US as well as the EU market. With improved outlook, ARBP has re-started the exercise to restructure the Eugia business and evaluate options to unlock the inherent value of its injectable business. * We raise our earnings estimate by 8%/7% for FY24/FY25, factoring a) su...
Neutral Aurobindo Pharma Ltd For Target Rs.910 - Motilal Oswal Financial Services
US/EU markets drive profitability Re-exploring restructuring of Eugia business * Aurobindo Pharma (ARBP) delivered operationally better-than-expected 1QFY24 performance, on the back of a healthy volume off-take in the US as well as the EU market. With improved outlook, ARBP has re-started the exercise to restructure the Eugia business and evaluate options to unlock the inherent value of its injectable business. * We raise our earnings estimate by 8%/7% for FY24/FY25, factoring a) superi...
Neutral Aurobindo Pharma Ltd For Target Rs.910 - Motilal Oswal Financial Services
Aurobindo Pharma is currently trading at Rs. 885.45, up by 22.40 points or 2.60% from its previous closing of Rs. 863.05 on the BSE. The scrip opened at Rs. 864.75 and has touched a high and low of Rs. 887.20 and Rs. 851.10 respectively. So far 58531 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 887.20 on 14-Aug-2023 and a 52 week low of Rs. 397.30 on 03-Feb-2023. Last one week high and low of the scrip s...
Aurobindo Pharma surges on reporting over 9% rise in Q1 consolidated net profit
Aurobindo Pharma surges as arm gets nod to manufacture, market Vancomycin Hydrochloride for injection Aug-07-2023 09:59 Hrs IST Aurobindo Pharma is currently trading at Rs. 863.90, up by 22.10 points or 2.63% from its previous closing of Rs. 841.80 on the BSE. The scrip opened at Rs. 843.25 and has touched a high and low of Rs. 864.45 and Rs. 839.70 respectively. So far 21288 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has tou...
Aurobindo Pharma surges as arm gets nod to manufacture, market Vancomycin Hydrochloride for injection
Aurobindo Pharma is currently trading at Rs. 826.00, up by 37.15 points or 4.71% from its previous closing of Rs. 788.85 on the BSE. The scrip opened at Rs. 798.00 and has touched a high and low of Rs. 829.50 and Rs. 792.10 respectively. So far 27014 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 829.50 on 27-Jul-2023 and a 52 week low of Rs. 397.30 on 03-Feb-2023. Last one week high and low of the scrip stood ...
Aurobindo Pharma shines on incorporating Wholly Owned Step-down Subsidiary in Russia
Aurobindo Pharma is currently trading at Rs. 788.65, up by 3.50 points or 0.45% from its previous closing of Rs. 785.15 on the BSE. The scrip opened at Rs. 775.45 and has touched a high and low of Rs. 791.40 and Rs. 775.45 respectively. So far 26313 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 791.85 on 24-Jul-2023 and a 52 week low of Rs. 397.30 on 03-Feb-2023. Last one week high and low of the scrip stood a...
Aurobindo Pharma gains after its arm gets USFDA`s final approval for Plerixafor Injection
India's Glenmark Life Sciences reported a near-25% rise in its first-quarter profit on Friday, led by robust growth of its mainstay active pharmaceutical ingredients (API) business in domestic as well as U.S. and European markets. The Mumbai-based drug maker said profit stood at 1.35 billion rupees ($16.5 million) for the quarter ended June 30, compared with 1.09 billion rupees a year earlier. The company, spun off from Glenmark Pharmaceuticals in 2019 to focus on the API business, ...
India`s Glenmark Life Sciences posts 25% rise in Q1 profit on API strength
Aurobindo Pharma (AURPHA) Ltd Buy Aurobindo Pharma (AURPHA) Ltd @751-752; Target 763.00; Stop Loss 745.90 State Bank of India Ltd Buy State Bank of India Ltd @588-589; Target 597.00; Stop Loss 583.90 To Read Complete Report & Disclaimer Click Here Please refer disclaimer at https://www.tradebulls.in/disclaimer SEBI Registration number is INZ000171838 &nbs...
Stock Picks : Aurobindo Pharma (AURPHA) Ltd and State Bank of India Ltd By ICICI Direct
* Aurobindo Pharma (ARBP) has entered into an exclusive license agreement with BioFactura to commercialize a proposed biosimilar of Stelara (Ustekinumab). ? With this agreement, ARBP has fast-tracked its pipeline for biosimilar offerings. * The company is on track to build key levers of growth – a) accelerating the biosimilar pipeline, b) enhancing the ANDA pipeline comprising complex products, c) leveraging the PLI scheme, and d) expanding its China operations. We value ARB...
Neutral Aurobindo Pharma Ltd For Target Rs.710 - Motilal Oswal Financial Services
Mahindra&Mahindra Ltd Buy Mahindra&Mahindra Ltd @1472-1475; Target 1491.00; Stop Loss 1466.00 Aurobindo Pharma Ltd Buy Aurobindo Pharma Ltd @730-732; Target 742.00; Stop Loss 726.30 To Read Complete Report & Disclaimer Click Here Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Disclaimer.html SEBI Registration number INZ000183631 Ab...
Stock Picks : Mahindra&Mahindra Ltd and Aurobindo Pharma Ltd By ICICI Direct
Aurobindo Pharma is currently trading at Rs. 714.60, up by 2.25 points or 0.32% from its previous closing of Rs. 712.35 on the BSE. The scrip opened at Rs. 712.45 and has touched a high and low of Rs. 718.30 and Rs. 709.00 respectively. So far 20246 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 741.40 on 28-Jun-2023 and a 52 week low of Rs. 397.30 on 03-Feb-2023. Last one week high and low of the scrip stood a...
Aurobindo Pharma trades higher as its group entity inks pact with Viatris
Aurobindo Pharma is currently trading at Rs. 696.05, up by 24.85 points or 3.70% from its previous closing of Rs. 671.20 on the BSE. The scrip opened at Rs. 671.00 and has touched a high and low of Rs. 700.85 and Rs. 665.65 respectively. So far 66365 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 700.85 on 23-Jun-2023 and a 52 week low of Rs. 397.30 on 03-Feb-2023. Last one week high and low of the scrip stood ...
Aurobindo Pharma surges as its arm inks voluntary license with Medicines Patent Pool
Earnings decline for second consecutive year Levers in place to deliver growth over next two years * Aurobindo Pharma (ARBP) delivered a better-than-expected operating performance in 4QFY23, driven by healthy growth in the US/EU/ROW formulation and API segments. In addition to robust ANDA filings, ARBP continues to work toward building a niche portfolio in the biosimilar/ peptide space. Its ambitious Pen-G project is also on track for commercialization in FY25. * We raise our FY24/FY...
Neutral Aurobindo Pharma Ltd For Target Rs.600 - Motilal Oswal Financial Services
Earnings decline for second consecutive year Levers in place to deliver growth over next two years * 4QFY23 sales grew 11% YoY to INR65b (est. INR63b). Total formulation sales rose 11% YoY to INR54.6b. US generics revenue grew 12% YoY to INR31b (flat YoY in CC terms at USD370m; 47% of sales). Growth Market sales jumped 51% YoY to INR6b (9% of sales). Europe formulation sales grew 8% YoY to INR16.6b (26% of sales). ARV sales declined 33% YoY to INR1.6b (2% of sales). API sales rose 11% Y...
Buy Aurobindo Pharma Ltd For Target Rs.600 - Motilal Oswal Financial Services
Aurobindo Pharma is currently trading at Rs. 628.50, up by 17.30 points or 2.83% from its previous closing of Rs. 611.20 on the BSE. The scrip opened at Rs. 611.25 and has touched a high and low of Rs. 654.95 and Rs. 611.25 respectively. So far 136309 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 654.95 on 30-May-2023 and a 52 week low of Rs. 397.30 on 03-Feb-2023. Last one week high and low of the scrip stood...
Aurobindo Pharma surges on getting nod to sell stake in Auro Vaccines
Balrampur Chini (BALCHI) Ltd Buy Balrampur Chini Ltd 385.00-386.00 CMP 384.60 ; Target 390.80; Stop Loss 382.20 Aurobindo Pharma Ltd Sell Aurobindo Pharma Ltd 605.00-608.00 CMP 599.80 ; Target 597.50; Stop Loss 612.70 To Read Complete Report & Disclaimer Click Here Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Disclaimer.html SEBI Registrati...
Stock Picks : Balrampur Chini Ltd and Aurobindo Pharma Ltd By ICICI Direct
Aurobindo Pharma is currently trading at Rs. 517.60, up by 7.80 points or 1.53% from its previous closing of Rs. 509.80 on the BSE. The scrip opened at Rs. 511.55 and has touched a high and low of Rs. 520.50 and Rs. 510.85 respectively. So far 89496 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 714.60 on 06-Apr-2022 and a 52 week low of Rs. 397.30 on 03-Feb-2023. Last one week high and low of the scrip stood a...
Aurobindo Pharma climbs on inking voluntary license with Medicines Patent Pool
Aurobindo Pharma Ltd Aurobindo Pharma Ltd @ 484-485 CMP486.00 Stop Loss 480.80 Target 491.30 Hindustan Unilever Ltd Hindustan Unilever Ltd @ 2479-2483 CMP 2485.10 Stop Loss 2461.40 Target 2514.00 To Read Complete Report & Disclaimer Click Here Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Disclaimer.html SEBI Registration num...
Stock Picks : Aurobindo Pharma Ltd and Hindustan Unilever Ltd By ICICI Direct
Improved margin outlook Result Synopsis Aurobindo Pharma reported a better quarter on back of some calm in the injectable as well as oral solids portfolio. Margin improved slightly QoQ though compared to last year base, price erosion in oral solids, increased freight costs still translated into persistent pressure on OPM. Aurobindo has indicated double digit growth in injectables in Q4 and Q1 FY24 which should assuage concern on the durability of the rebound in the near term. Oral so...
Buy Aurobindo Pharma Ltd For Target Rs.650 - Yes Securities
Aurobindo Pharma is currently trading at Rs. 452.55, up by 11.85 points or 2.69% from its previous closing of Rs. 440.70 on the BSE. The scrip opened at Rs. 445.10 and has touched a high and low of Rs. 459.15 and Rs. 445.10 respectively. So far 49321 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 730.00 on 25-Mar-2022 and a 52 week low of Rs. 397.30 on 03-Feb-2023. Last one week high and low of the scrip stood ...
Aurobindo Pharma shines on getting nod to transfer of API Non-Antibiotic Division to Auro Pharma India
Aurobindo Pharma is currently trading at Rs. 423.00, up by 4.35 points or 1.04% from its previous closing of Rs. 418.65 on the BSE. The scrip opened at Rs. 419.10 and has touched a high and low of Rs. 424.15 and Rs. 415.35 respectively. So far 34505 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 730.00 on 25-Mar-2022 and a 52 week low of Rs. 397.30 on 03-Feb-2023. Last one week high and low of the scrip stood a...
Aurobindo Pharma gains as its arm receives USFDA`s approval for Diclofenac Sodium Topical Solution USP
Aurobindo Pharma is currently trading at Rs. 442.50, up by 1.30 points or 0.29% from its previous closing of Rs. 441.20 on the BSE. The scrip opened at Rs. 444.75 and has touched a high and low of Rs. 445.00 and Rs. 440.10 respectively. So far 17669 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 742.25 on 11-Jan-2022 and a 52 week low of Rs. 429.30 on 02-Jan-2023. Last one week high and low of the scrip stood a...
Aurobindo Pharma gains as its arm gets final approval from USFDA for Azacitidine Injection
Aurobindo Pharma is currently trading at Rs. 442.75, up by 5.50 points or 1.26% from its previous closing of Rs. 437.25 on the BSE. The scrip opened at Rs. 440.40 and has touched a high and low of Rs. 444.80 and Rs. 438.40 respectively. So far 102108 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 742.25 on 11-Jan-2022 and a 52 week low of Rs. 434.40 on 26-Dec-2022. Last one week high and low of the scrip stood ...
Aurobindo Pharma gains after its JV receives SEC recommendation for pneumococcal 15 valent vaccine
Price erosion in the US and higher OPEX impacts earning US outlook an area of worry; downgrade the stock to Neutral * ARBP delivered a 2QYF23 earnings miss, led by lower-than-expected US and ARV sales. Sales from Europe (EU) were stable YoY in CC terms, with a pickup in API sales. * We cut our FY23/FY24 earnings estimate by 18%/13% to factor in: a) reduced demand for Injectables, led by shelf stock adjustment, b) considerable price erosion in the base portfolio in the US segment, c) ...
Neutral Aurobindo Pharma Ltd For Target Rs.500 - Motilal Oswal Financial Services
Aurobindo unit, Evive Biotech ink pact to sell CIN treatment product in US Aurobindo Pharma on Wednesday said its unit has entered into a licensing pact with Evive Biotech to commercialise Ryzneuta in the US market. The product, a novel dimeric G-CSF long-acting fusion protein without pegylation, is currently under late-stage review by the US Food and Drug Administration for chemotherapy-induced neutropenia (CIN). Air India expands its US, Europe network with new non-stop flig...
Key Stock News: Aurobindo Pharma, Air India, Lanco Amarkantak Power, Adani Enterprises, Wipro - ARETE Securities
Aurobindo Pharma is currently trading at Rs. 463.60, up by 2.90 points or 0.63% from its previous closing of Rs. 460.70 on the BSE. The scrip opened at Rs. 461.05 and has touched a high and low of Rs. 464.85 and Rs. 461.05 respectively. So far 5545 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 742.25 on 11-Jan-2022 and a 52 week low of Rs. 457.20 on 14-Nov-2022. Last one week high and low of the scrip stood at...
Aurobindo Pharma moves up on aiming to complete Pen G plant in Andhra Pradesh by March 2024
Aurobindo Pharma Ltd learnt Sarath Chandra Reddy, its whole time director, had been arrested by enforcement directorate, the Indian drugmaker said in an exchange filing on Thursday. The company, whose shares were down 6%, did not respond to Reuters' request for details on the arrest.
Indian drugmaker Aurobindo Pharma says its director arrested by enforcement directorate
Aurobindo Pharma is currently trading at Rs. 522.00, up by 1.50 points or 0.29% from its previous closing of Rs. 520.50 on the BSE. The scrip opened at Rs. 518.05 and has touched a high and low of Rs. 529.45 and Rs. 516.60 respectively. So far 24603 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 751.45 on 04-Oct-2021 and a 52 week low of Rs. 503.40 on 20-Jun-2022. Last one week high and low of the scrip stood a...
Aurobindo Pharma inches up as its arm receives EIR for Raleigh plant
The Indian pharma industry is expected to grow to $130 billion by 2030 and become the leading provider of medicines to the world, said Indian Pharmaceutical Alliance (IPA) Secretary General, Sudarshan Jain on Thursday. The Indian pharma industry is currently valued at $49 billion and is the third largest in the world. India supplied medicines to over 200 countries in the world, he said. He was speaking on the sidelines of three-day trade shows on laboratory technology and Pharma - machi...
Indian pharma industry likely to grow to $130 bn by 2030
Aurobindo Pharma is currently trading at Rs. 539.40, up by 4.80 points or 0.90% from its previous closing of Rs. 534.60 on the BSE. The scrip opened at Rs. 536.50 and has touched a high and low of Rs. 542.90 and Rs. 536.10 respectively. So far 15536 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 767.45 on 15-Sep-2021 and a 52 week low of Rs. 503.40 on 20-Jun-2022. Last one week high and low of the scrip stood a...
Aurobindo Pharma rises as its arm gets nod to expand mammalian cell culture manufacturing facility
* AUROPHARMA has been under pressure since quiet some time but at this juncture its trading near its crucial support. * Previously the stock turned from this level and we saw a rally towards 820 APPROX. * On DAILY chart AUROPHARMA has bullish crab harmonic pattern which is looking lucrative. * Thus we advise traders to go long in the stock with a stop loss of 472 Buy Cochin Shipyard Ltd CMP: 540, STOP LOSS 472, TARGET 675 To Read Complete Report &am...
Buy Aurobindo Pharma Limited For Target Rs.675 - Anand Rathi Share and Stock Brokers
Aurobindo Pharma is currently trading at Rs. 583.95, up by 3.55 points or 0.61% from its previous closing of Rs. 580.40 on the BSE. The scrip opened at Rs. 579.45 and has touched a high and low of Rs. 586.35 and Rs. 566.60 respectively. So far 98079 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 767.45 on 15-Sep-2021 and a 52 week low of Rs. 503.40 on 20-Jun-2022. Last one week high and low of the scrip stood a...
Aurobindo Pharma jumps on acquiring 51% stake in GLS Pharma
Bottoming out of margin, valuation attractive Result Synopsis??????? Aurobindo Pharma reported a better US performance after several quarters of disappointment as US revenues rose 9% QoQ; price erosion seems to have moderated compared to 4Q while company catered to additional volume opportunities. Other segments like ARV, API and growth markets too rebounded barring Europe. Company underwent another round of input cost pressure as gross margin further compressed QoQ coupled with price e...
Buy Aurobindo Pharma Ltd For Target Rs.750- Yes Securities
Aurobindo Pharma is currently trading at Rs. 596.90, up by 3.60 points or 0.61% from its previous closing of Rs. 593.30 on the BSE. The scrip opened at Rs. 594.00 and has touched a high and low of Rs. 602.75 and Rs. 592.90 respectively. So far 29574 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 821.75 on 13-Aug-2021 and a 52 week low of Rs. 503.40 on 20-Jun-2022. Last one week high and low of the scrip stood a...
Aurobindo Pharma moves up as its arm receives USFDA`s approval for Vasopressin Injection
Key News ADIA to invest Rs 665 cr in Aditya Birla Health Insurance for 9.99% stake The boards of Aditya Birla Capital and Aditya Birla Health Insurance have approved a proposal of capital infusion to the tune of Rs 665 crore in the later from a subsidiary of Abu Dhabi Investment Authority (ADIA), the company said in a late-night statement. Aditya Birla Health Insurance is a 51:49 joint venture between Aditya Birla Capital Limited and Momentum Metropolitan Strategic Investments, a wh...
Key Stock News - Aditya Birla Health Insurance, Zerodha, Adani Group, Aurobindo Pharma, Bata India Ltd - ARETE Securities
US Food and Drug Administration (USFDA) has issued Form 483 with three observations after inspecting Aurobindo Pharma’s manufacturing facility at Pydibhimavaram in Andhra Pradesh. As per USFDA, Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that in its judgement may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts. The Pydibhimavaram unit was classified as OAI (offic...
Aurobindo Pharma gets 3 observations from USFDA for Andhra Pradesh unit
Key News JSW in talks with PEs, foreign banks for Mytrah Energy acquisition The JSW group has initiated talks with several private equity (PE) funds, including American investment management firm Apollo Global Management, to acquire its renewable power producer, Mytrah Energy (India) Pvt Ltd (MEIPL). The firm’s acquisition amount will be announced next month, banking sources said. The current enterprise valuation is $2 billion. JSW group’s JSW Energy has a target to add 15 g...
Key Stock News - JSW group, Aurobindo Pharma, Adani Group, Tata Motors, Avenue Supermarts Ltd By ARETE Securities
Aurobindo Pharma is currently trading at Rs. 542.05, up by 8.75 points or 1.64% from its previous closing of Rs. 533.30 on the BSE. The scrip opened at Rs. 531.45 and has touched a high and low of Rs. 543.45 and Rs. 530.00 respectively. So far 32014 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1003.85 on 06-Jul-2021 and a 52 week low of Rs. 503.40 on 20-Jun-2022. Last one week high and low of the scrip stood ...
Aurobindo Pharma trades higher as its arm gets USFDA nod for Triamcinolone Acetonide injectable suspension
Aurobindo Pharma has completed the acquisition of business and certain assets of Veritaz Healthcare. Earlier, the company had received approval of the Board of Directors of the Company for the acquisition of the same. Veritaz operates in pharmaceutical industry in India and sells branded generic formulations and other health care related products. Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic ...
Aurobindo Pharma acquires business and certain assets of Veritaz Healthcare
Aurobindo Pharma is currently trading at Rs. 520.70, up by 4.35 points or 0.84% from its previous closing of Rs. 516.35 on the BSE. The scrip opened at Rs. 518.00 and has touched a high and low of Rs. 524.60 and Rs. 512.25 respectively. So far 75491 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1017.15 on 14-Jun-2021 and a 52 week low of Rs. 511.80 on 07-Jun-2022. Last one week high and low of the scrip stood ...
Aurobindo Pharma jumps after its arm gets USFDA approval for Leuprolide Acetate injection
Aurobindo Pharma is currently trading at Rs. 532.75, down by 8.25 points or 1.52% from its previous closing of Rs. 541.00 on the BSE. The scrip opened at Rs. 541.20 and has touched a high and low of Rs. 546.50 and Rs. 527.40 respectively. So far 346162 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1017.15 on 14-Jun-2021 and a 52 week low of Rs. 514.50 on 25-May-2022. Last one week high and low of the scrip sto...
Aurobindo Pharma declines on reporting 28% fall in Q4 consolidated net profit
Margin up cycle on the cards Result Synopsis Aurobindo Pharma clocked a better gross margin performance QoQ as mix improved along with some price pass-through in external API sales. Management appeared surprised by the sequential 2.5% price erosion in US business and now expects such pricing pressure to persist for next 1-2 quarters. Albeit, higher injectable sales on a weak base of past 2 years should support margin. US injectable sales have gone nowhere since high watermark of ~US$270...
Buy Aurobindo Pharma Ltd For Target Rs.770 - Yes Securities
In line; see cost headwinds over the near term Work-in-progress to build a niche product pipeline * ARBP delivered an in line 4QFY22. Increased competitive intensity in US Generics and higher OPEX impacted profitability in 4QY22 on a YoY basis. * We cut our FY23/FY24 EPS estimate by 9%/12%, factoring in: a) a higher price erosion in the US base business, b) greater RM/logistics cost, and c) moderation in the EU/ARV business. We value ARBP at 12x 12M forward earnings to arrive at...
Buy Aurobindo Pharma Ltd For Target Rs. 640 - Motilal Oswal
The company reported standalone net profit of Rs 802.16 crore for the quarter ended March 31, 2022 as compared to Rs 872.58 crore in the same period last year, registering a year-on-year decline of 8.07 per cent. Net revenue of the company declined substantially by 29.87 per cent at Rs 2,877.83 crore in January-March quarter of this fiscal as against Rs 4,103.61 crore in the corresponding period last year. During January-March quarter, operating expenses dropped by 24.15 per cent to Rs 2,3...
Aurobindo Pharma Q4 net profit down 8.07% at Rs 802.16 cr
Aurobindo Pharma is currently trading at Rs. 528.45, up by 5.30 points or 1.01% from its previous closing of Rs. 523.15 on the BSE. The scrip opened at Rs. 531.15 and has touched a high and low of Rs. 531.30 and Rs. 518.30 respectively. So far 77248 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1043.00 on 26-May-2021 and a 52 week low of Rs. 514.50 on 25-May-2022. Last one week high and low of the scrip stood ...
Aurobindo Pharma surges as its arm gets USFDA’s final approval for Pemetrexed for Injection
Hindustan Unilever Ltd Buy Hindustan Unilever Ltd @ 2181.00-2183.00 CMP 2183.70 Stop Loss 2160.30 Target 2203.60/2225.00 Aurobindo Pharma Ltd Sell Aurobindo Pharma Ltd @ 602.00-604.00 CMP 604.10 Stop Loss 609.20 Target 597.2/590.60 To Read Complete Report & Disclaimer Click Here https://secure.icicidirect.com/Content/StaticData/Discla...
Stock Picks - Hindustan Unilever Ltd and Aurobindo Pharma Ltd By ICICI Direct
Load More
